4 hours ago
Patients with non-segmental vitiligo (NSV) on upadacitinib versus placebo showed continuous improvement over 48 weeks with no plateau.
4 hours ago
As patients increasingly turn to ChatGPT for mental health support, psychiatrists and ethicists weigh the clinical risks, ethical concerns, and what clinicians should do next.
5 hours ago
New information from the phase 3 SCOUT-HCM trial indicate the benefits of mavacamten may extend to adolescents as well as adults.
7 hours ago
Chovatiya discussed new data showing significant EASI improvements across moderate and severe atopic dermatitis.
8 hours ago
Results from the phase 3 trial were published in NEJM and simultaneously presented as a late-breaking abstract at AAD 2026.